Expert NetworkExpert InterviewLLY

Slingshot members are talking to an expert! The topic is:

A look at the pending PDUFA of tirzepatide and how it may compare to Rybelsus (semaglutide) and the Type 2 diabetes space as a whole

Executed on:Apr 21, 2022 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Harvard Medical School
  • Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor at Harvard Medical School.
  • Manages ~1,000 patients with diabetes and obesity
  • Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss. 

Interview Goal

Discuss the outlook for tirzepatide in type 2 diabetes

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.